Figure 1: TKI response of PC9 and PC9/gef cell lines and EGFR phosphorylation profile. | Scientific Reports

Figure 1: TKI response of PC9 and PC9/gef cell lines and EGFR phosphorylation profile.

From: Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer

Figure 1

(a) Cell survival rates of PC9 and PC9/gef cells under treatment with various concentrations of gefitinib. (b) Phosphorylation profile of EGFR kinase active sites with or without EGF stimulation. Site-specific antibodies against pY1148, pY1173, pY1086 and pY1045 were used for western blot detection. The intensity of phosphorylation sites were normalized to the intensity of total EGFR protein intensity in comparison analysis. (c) Experimental workflow of the quantitative proteomic and phosphoproteomic analysis of TKI-sensitive PC9 and TKI-resistant PC9/gef cells under gefitinib treatment (10 μM and 20 μM). The label-free quantitation approach integrated gel-assisted digestion and pH/acid-controlled IMAC for phosphopeptide purification. After IMAC purification, the eluted fraction was used for phosphoproteome analysis, while the flow-through fraction was used for protein-level quantitation. The quantitation of protein and phosphopeptides was performed using Ideal-Q software.

Back to article page